Plaidoyer pour le dépistage échographique systématique précoce des toxicités cardiovasculaires post-traitement par cyclophosphamide-doxorubicine-vincristine-prednisone avec ou sans rituximab Volume 26, issue 3, Mai-Juin 2020

  • [1] Baech J., Hansen S.M., Lund P.E., Soegaard P. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol. 2018;183:7-726.
  • [2] Linschoten M., Kamphuis J.A.M., Van Rhenen. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, vincriostine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7:e295-e308.
  • [3] Fornaro A., Olivotto I., Rigacci L. Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. Eur J Heart Fail. 2018;20:898-906.
  • [4] Cardinale D., Colombo A., Bacchiani G. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981-1988.
  • [5] Curigliano G., Lenihan D., Fradley M. ESMO Guidelines Committee. Electronic address : clinicalguidelines@esmo. org. Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:171-190.